dalteparin has been researched along with Brain Edema in 5 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Brain Edema: Increased intracellular or extracellular fluid in brain tissue. Cytotoxic brain edema (swelling due to increased intracellular fluid) is indicative of a disturbance in cell metabolism, and is commonly associated with hypoxic or ischemic injuries (see HYPOXIA, BRAIN). An increase in extracellular fluid may be caused by increased brain capillary permeability (vasogenic edema), an osmotic gradient, local blockages in interstitial fluid pathways, or by obstruction of CSF flow (e.g., obstructive HYDROCEPHALUS). (From Childs Nerv Syst 1992 Sep; 8(6):301-6)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Suto, Y | 1 |
| Nagata, K | 2 |
| Ahmed, SM | 1 |
| Jacovides, CL | 1 |
| Browne, KD | 3 |
| Cognetti, J | 1 |
| Johnson, VE | 3 |
| Leone, R | 1 |
| Kaplan, LJ | 1 |
| Smith, DH | 3 |
| Pascual, JL | 3 |
| Li, S | 2 |
| Marks, JA | 1 |
| Eisenstadt, R | 2 |
| Kumasaka, K | 2 |
| Samadi, D | 1 |
| Holena, DN | 1 |
| Allen, SR | 1 |
| Marks, J | 1 |
| Wahl, F | 2 |
| Grosjean-Piot, O | 2 |
| Bareyre, F | 1 |
| Uzan, A | 2 |
| Stutzmann, JM | 2 |
| Mary, V | 1 |
| Pratt, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Improving Outcome in Subarachnoid Hemorrhage wIth Nadroparine[NCT04507178] | Phase 2 | 100 participants (Anticipated) | Interventional | 2022-02-02 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for dalteparin and Brain Edema
| Article | Year |
|---|---|
Neuroprotective profile of enoxaparin, a low molecular weight heparin, in in vivo models of cerebral ischemia or traumatic brain injury in rats: a review.
Topics: Animals; Anticoagulants; Brain Edema; Brain Injuries; Brain Ischemia; Cognition Disorders; Enoxapari | 2002 |
4 other studies available for dalteparin and Brain Edema
| Article | Year |
|---|---|
Cerebral Edema and Neurological Recovery after Traumatic Brain Injury Are Worsened if Accompanied by a Concomitant Long Bone Fracture.
Topics: Animals; Anticoagulants; Brain Edema; Brain Injuries, Traumatic; Enoxaparin; Fractures, Bone; Male; | 2019 |
Enoxaparin ameliorates post-traumatic brain injury edema and neurologic recovery, reducing cerebral leukocyte endothelial interactions and vessel permeability in vivo.
Topics: Animals; Anticoagulants; Brain Edema; Brain Injuries; Endothelium, Vascular; Enoxaparin; Leukocytes; | 2015 |
Does enoxaparin interfere with HMGB1 signaling after TBI? A potential mechanism for reduced cerebral edema and neurologic recovery.
Topics: Animals; Antibodies, Monoclonal; Anticoagulants; Brain; Brain Edema; Brain Injuries; Cerebrovascular | 2016 |
Enoxaparin reduces brain edema, cerebral lesions, and improves motor and cognitive impairments induced by a traumatic brain injury in rats.
Topics: Animals; Anticoagulants; Body Water; Brain; Brain Edema; Brain Injuries; Cognition; Cognition Disord | 2000 |